NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Trethera Corporation Developing TRE-515 to Treat Myelodyspastic Syndromes and Acute Myeloid Leukemia

TRE-515 Therapy Targets Multiple Pathways to Improve Treatment Efficacy Over Single-Agent Approaches Trethera Corporation, a Los Angeles-based clinical-stage biopharmaceutical company, is developing cancer treatments for orphan blood cancers with high unmet needs.  Trethera’s lead program combines TRE-515, a novel deoxycytidine kinase inhibitor, with de novo pathway inhibitors. TRE-515 has been chemically engineered to improve bioavailability and demonstrates robust anti-tumor activity in combination therapies.  By targeting multiple pathways using rationally-designed combinations of drugs, Trethera’s therapeutic approaches may improve treatment efficacy and overcome the limitations of single-agent therapies. The dual blockade of nucleotide synthesis may additionally minimize the development of drug resistance. TRE-515 is being developed to treat myelodyspastic syndromes (MDS), acute myeloid leukemia, and potentially other hematological neoplasms and solid tumor indications.  MDS, which primarily afflicts the elderly, is a type of cancer with significant morbidity and high mortality. MDS leads to bone marrow failure, with about one-third of patients developing acute myeloid leukemia.  Trethera has developed an orally-available form of TRE-515 to address the needs of patients and providers. In February of 2018, the U.S.  Food and Drug Administration approved Trethera Corporation’s Investigational New Drug application for TRE-515.  Trethera is currently initiating a Phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TRE-515.  The Phase I study will also seek to validate several biomarkers in relapsed and/or refractory MDS patients who have no available alternative therapy.  In both the U.S and all major markets abroad, Trethera has secured a robust intellectual property position around TRE-515, and expects that TRE-515 will qualify as an Orphan Indication in the U.S. and Europe. Trethera Corporation was founded in 2013 and most recently raised $19.1M in seed-stage capital.  In upcoming news, Trethera is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City.  Learn more and register to attend the conference at www.nyconcologyconference.com.

To continue reading, please Login or Join